Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Are all benzodiazepines clinically equivalent?

Y D Lapierre

    Progress in Neuro-Psychopharmacology & Biological Psychiatry
    |January 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Understanding benzodiazepine pharmacokinetics and pharmacodynamics is crucial for effective clinical management. This study explores how drug levels relate to therapeutic effects and side effects for better patient outcomes.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Fluphenazine, trifluoperazine and perphenazine in Vacutainers.

    Canadian Medical Association journal·2010
    Same author

    What are the issues surrounding long-term benzodiazepine treatment for generalized anxiety disorder.

    Journal of psychiatry & neuroscience : JPN·2001
    Same author

    Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder.

    American journal of medical genetics·2000
    Same author

    Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia.

    Canadian journal of psychiatry. Revue canadienne de psychiatrie·1999
    Same author

    Obsessive-compulsive spectrum disorders: effective treatment with paroxetine.

    Canadian journal of psychiatry. Revue canadienne de psychiatrie·1999
    Same author

    Norepinephrine transporter gene polymorphism is not associated with susceptibility to major depression.

    Psychiatry research·1999
    Same journal

    Altered dorsal striatal subregional connectivity associated with distinct executive function deficits in first-episode, drug-naïve major depressive disorder: Evidence from functional connectivity and granger causality analysis.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    Same journal

    Chronic pain and stress: unravelling the common neuroinflammatory, immune and endocrine mechanisms for novel therapeutic approaches.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    Same journal

    Predicting anhedonia and negative cognitive processing changes after 8-week SSRIs treatment in depression from individual differential structural covariance network.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    Same journal

    Mapping intrinsic neural timescale alterations in major depressive disorder.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    Same journal

    Probiotics in reducing negative symptoms of schizophrenia: A systematic review and meta-analysis.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    Same journal

    The IL10 rs1800872 polymorphism differentially modulates the relationship between plasma IL-10 levels and cognitive function in methamphetamine use disorder.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Clinical Therapeutics
    • Neuroscience

    Background:

    • Clinical observations of drug efficacy sometimes diverge from laboratory pharmacokinetic data.
    • Benzodiazepines like chlordiazepoxide, diazepam, and oxazepam exhibit varied therapeutic profiles.
    • Triazolobenzodiazepines introduce novel primary and side effects in treatment.

    Purpose of the Study:

    • To examine the correlation between benzodiazepine blood levels and clinical efficacy.
    • To provide insights into managing anxious patients using pharmacokinetic and pharmacodynamic data.
    • To address issues of tolerance and dosage escalation in benzodiazepine therapy.

    Main Methods:

    • Review of clinical observations and laboratory pharmacokinetic/pharmacodynamic findings.

    Related Experiment Videos

  • Analysis of the therapeutic profiles of chlordiazepoxide, diazepam, oxazepam, and triazolobenzodiazepines.
  • Consideration of the relationship between drug blood levels and clinical outcomes.

    • Main Results:

    • Pharmacokinetics (half-life) do not always predict pharmacodynamics (clinical duration of action).
    • Different benzodiazepines and their metabolites (e.g., oxazepam) possess distinct therapeutic effects.
    • Triazolobenzodiazepines present unique efficacy and adverse effect profiles.

    Conclusions:

    • The relationship between blood levels and clinical efficacy is complex and requires careful consideration.
    • Integrating pharmacokinetic and pharmacodynamic data aids in optimizing benzodiazepine therapy.
    • Managing tolerance and dosage escalation is essential for safe and effective benzodiazepine use in anxious patients.